Menarini
Menarini Group, a prominent player in the pharmaceutical industry, is headquartered in Florence, Italy. Founded in 1886, the company has established a strong presence across Europe, Asia, and the Americas, focusing on research, development, and the manufacturing of innovative healthcare solutions. Specialising in prescription pharmaceuticals, over-the-counter products, and diagnostics, Menarini is recognised for its commitment to quality and patient care. The company’s core offerings include therapeutic areas such as oncology, cardiology, and infectious diseases, distinguished by their efficacy and safety profiles. With a rich history of milestones, Menarini has achieved significant market position, consistently ranking among the top pharmaceutical companies in Italy. Its dedication to advancing medical science and improving patient outcomes underscores its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Menarini's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Menarini's score of 26 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Menarini's reported carbon emissions
In 2023, Menarini reported total carbon emissions of approximately 1,250,770 kg CO2e, comprising 100,390 kg CO2e from Scope 1, 26,250 kg CO2e from Scope 2, and 1,125,130 kg CO2e from Scope 3 emissions. This marks a significant increase in emissions compared to previous years, with total emissions recorded at 46,000 kg CO2e in 2022, 43,000 kg CO2e in 2021, and 27,000 kg CO2e in 2020. Menarini's emissions profile indicates a growing reliance on Scope 3 emissions, which accounted for the majority of their carbon footprint in 2023. Despite the increase in total emissions, there are currently no publicly disclosed reduction targets or initiatives aimed at mitigating these emissions. The company is headquartered in Italy and is part of a broader industry context where pharmaceutical companies are increasingly focusing on sustainability and climate commitments. However, without specific reduction targets or pledges, Menarini's climate strategy remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 15,000 | 00,000 | 00,000 | 000,000 |
| Scope 2 | 12,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Menarini is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
